I am not misinformed, perhaps you are though, Stephen. In my experience physicians know very little about psychology and psychiatry. I will not be visiting this board after today for I will be selling the remainder of my ABBV shares today (due to the Shire purchase). I bought long ago pre spinoff and have profited handsomely from my position in abt/abbv. Due to the tax implications of this deal I may be exiting early here but I am doing so for reasons of conscience. I understand everyone has different values and I respect that. I personally will have no part in providing amphetamines for kids in America or anywhere in the world.
the drug reps go to psychiatrists and the psychiatrists are essentially the drug pushers (along with schools pushing parents into it as a fix for over active kids.) Bad parenting, kids consuming too much sugar and/or caffeine, not enough exercise... these are the root of the problem which is made far worse by a system which feels it's easier to pump kids full of drugs than raising them properly.
btw - pediatricians do no prescribe psychiatric drugs. Only psychiatrists may do that.
vingo - the doctors who prescribe speed to kids are absolutely on my black list. highly unethical and it's very bad for our society's future. we can't raise kids with hard drugs. adderall and vyvanse are among the brand names for FDA sanctioned amphetamines. Both are Shire drugs.
that's cool. the platform must be signaling with the color change that they are not open market orders. I wish trade architect would do that
it's PE speak for, "ok you guys are gonna leak about the deal talks to pump up the price then we are gonna leak to the press that the deal may not happen due to the, ah.. complex license agreements" opaque enough for you?? :)
"Not sure how he would be perceived by Apple if he somehow got a deal done with Samsung."
that's the beautiful thing about being carl icahn.... he doesn't care! lol
there are certainly risks on both sides of the trade. definitely more risk on the short side, since successful P2 will likely propel INO shares over 100% from here. probably not a binary event for long term holders of the stock as INO's pipeline is extensive. I am bullish given the industry's accolades given to vgx3100, plus the increasing institutional ownership coupled with all the boiler room tactics trying to tear the stock price down.
no offense, but I couldn't care less if north korea wins the world cup. any sport with the theatrics of soccer is not the sport for me. I've always found it over the top when nba players go fishing for offensive fouls... but they are nothing compared to sissy "football" players pretending they've hurt their teeth after biting another player. hilarious...
So are the red thumbs because you people want society pumping amphetamines into ten year old kids??? That is a big money maker for shire. But Abbvie shouldn't touch it.
if p2 topline fails he will write another blog bragging about he was right. If it doesn't he will not write anything about INO, at least not for a while. he wouldn't own up to being wrong. And if we get mixed results with strong t-cell data he will try to spin it that he's right - after p2 results he will have less sway over INO price when investors have hard data in hand.
personally I think AF is flat out wrong. The vaccine industry seems to disagree with AF. We shall see soon :)
nice, thanks for sharing. Peggy is no lightweight.
VANCOUVER, B.C., Feb. 12, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation...today announced the appointment of Ms. Peggy Phillips to its Board of Directors.
"Peggy's appointment and expertise is consistent with our focus on product development. We're confident that her extensive biotechnology experience, senior executive background, and considerable drug development expertise will translate to valuable contributions to our Board and company," said Dr. Mark J. Murray, Tekmira's President and CEO.
The appointment of Ms. Phillips fills the vacancy created in January 2014 when Dr. Michael Abrams resigned from the Board of Directors in order to assume his current role as Tekmira's Chief Discovery Officer. The total number of directors remains at six.
Ms. Phillips was on the Board of Immunex and served as the Chief Operating Officer from 1999 until the company was acquired by Amgen in 2002. During her sixteen-year career at Immunex, she held positions of increasing responsibility in research, development, manufacturing, sales, and marketing. As General Manager for Enbrel, she was responsible for clinical development, process development and regulatory affairs as well as the launch, sales and marketing of the product. Prior to joining Immunex, Ms. Phillips worked at Miles Laboratories for ten years. Ms. Phillips currently sits on the Board of Directors of Dynavax Technologies (Nasdaq:DVAX), a clinical stage biopharmaceutical company. Ms. Phillips holds a B.S. and a M.S. in microbiology from the University of Idaho.
I am hoping abbvie doesn't end up purchasing shire. I would have to sell my abbv shares; I am morally opposed to pushing amphetamines to kids. (re: adderall is a shire drug)
I haven't seen a full teardown yet but Ifixit did one on June 18. They posted it on youtube, go there and search: 'oneplus one teardown review'
Pause the video at about 2:30..... the chip outlined in yellow, reads upside down: agd2 2402 wx9dr
I searched 'agd2 2402 wx9dr' and found nothing, however when I searched 'agd2 gyro' I found that it's STM.
I don't think anyone was expecting invn to get the gyro in this phone so no worries. I am hopeful for other invn design wins in the new fire. As well as a whole slew of new products utilizing invn tech.